Frequency of deviant immunological test values in chronic fatigue syndrome patients.
Natelson, B H, Ellis, S P, Braonáin, P J et al. · Clinical and diagnostic laboratory immunology · 1995 · DOI
Quick Summary
Researchers tested 11 different immune system markers in ME/CFS patients and compared them to fatigued people without ME/CFS. They found that three immune tests (protein A binding, Raji cell test, and complement proteins C3 or C4) showed different results between the groups. However, most other immune tests they looked at, including antibody levels and other complement markers, did not reliably distinguish ME/CFS patients from those with other causes of fatigue.
Why It Matters
Identifying reliable immune biomarkers is crucial for developing objective diagnostic tests for ME/CFS, which currently relies on clinical criteria alone. This study contributes to understanding which immune abnormalities are potentially specific to ME/CFS versus other fatigue-causing conditions. Such biomarkers could eventually help clinicians diagnose the disease more confidently and support research into disease mechanisms.
Observed Findings
Three immunological tests showed deviant values that discriminated between ME/CFS patients and fatigued controls: protein A binding, Raji cell test, and complement components C3 or C4
Immunoglobulin G subclasses did not discriminate well between groups
Complement component CH50 did not discriminate well between groups
Interleukin-2 levels did not discriminate well between groups
Anticardiolipin antibodies did not discriminate well between groups
Inferred Conclusions
Certain complement pathway abnormalities and specific immune cell binding patterns may represent biological markers associated with ME/CFS
Many commonly measured immune parameters do not reliably differentiate ME/CFS from other fatigue conditions
A targeted panel of immune tests (protein A binding, Raji cell, complement components) may be more useful for diagnostic purposes than broad immunological screening
Remaining Questions
Are the three discriminating immune markers present in all ME/CFS patients, or only in a subset, and what is their clinical sensitivity and specificity?
Do these immune abnormalities correlate with disease severity, symptom duration, or patient outcomes?
What This Study Does Not Prove
This study does not prove that abnormal protein A binding, Raji cell, or complement levels cause ME/CFS—it only shows an association. It also does not establish whether these immune markers are consistently present in all ME/CFS patients or whether they appear in other conditions. The findings cannot be generalized beyond the specific population studied or confirm clinical utility of these tests in routine practice.